Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

121. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Kennedy T M, Chalder T, McCrone P, Darnley S, Knapp M, Jones R H, Wessely S (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kennedy T M, Chalder T, McCrone P, Darnley S, Knapp M, Jones R H, Wessely S. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technology Assessment 2006; 10(19): 1-84 Authors' objectives The aim

Health Technology Assessment (HTA) Database.2006

122. A self help guidebook reduced primary care consultations in irritable bowel syndrome

A self help guidebook reduced primary care consultations in irritable bowel syndrome A self help guidebook reduced primary care consultations in irritable bowel syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A self help guidebook reduced primary care consultations in irritable bowel syndrome Article Text Therapeutics A self help guidebook reduced primary care consultations in irritable bowel syndrome Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all

Evidence-Based Medicine (Requires free registration)2006

123. Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome

Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Article Text Therapeutics Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Free G Richard

Evidence-Based Medicine (Requires free registration)2005

124. Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action

Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Tan G, Hammond D C, Gurrala J CRD summary This review concluded that variations on a protocol for hypnosis represent an effective therapy for reducing symptoms of irritable bowel syndrome and improving emotional and quality-of-life outcomes (...) in the long term. Several significant limitations in the review process, along with the paucity of the evidence reviewed, suggest that the authors' conclusions may be overstated and not particularly robust. Authors' objectives To assess the efficacy of hypnosis in reducing the symptoms and in improving emotional and quality-of-life outcomes associated with irritable bowel syndrome (IBS), and to examine the possible mechanisms of action. Searching The authors searched PubMed and PsycLIT, along with medical

DARE.2005

125. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.

Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. 16093252 2005 08 19 2005 08 29 2014 06 06 1756-1833 331 7514 2005 Aug 20 BMJ (Clinical research ed.) BMJ Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. 435 To assess the efficacy of cognitive behaviour therapy delivered in primary care for treating irritable bowel syndrome (...) . Randomised controlled trial. 10 general practices in London. 149 patients with moderate or severe irritable bowel syndrome resistant to the antispasmodic mebeverine. Cognitive behaviour therapy delivered by trained primary care nurses plus 270 mg mebeverine taken thrice daily compared with mebeverine treatment alone. Primary measures were patients' scores on the irritable bowel syndrome symptom severity scale. Secondary measures were scores on the work and social adjustment scale and the hospital anxiety

BMJ2005 Full Text: Link to full Text with Trip Pro

126. Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome

Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Article Text Economics Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Free Filippo

Evidence-Based Medicine (Requires free registration)2004

127. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. CONTEXT: Irritable bowel syndrome (IBS), which affects 11% to 14% of the population, is a puzzling condition with multiple models of pathophysiology including altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation. Although no conceptual framework accounts for all the symptoms and observations in IBS, a unifying explanation may exist (...) since 92% of these patients share the symptom of bloating regardless of their predominant complaint. EVIDENCE ACQUISITION: Ovid MEDLINE was searched through May 2004 for relevant English-language articles beginning with those related to bloating, gas, and IBS. Bibliographies of pertinent articles and books were also scanned for additional suitable citations. EVIDENCE SYNTHESIS: The possibility that small intestinal bacterial overgrowth (SIBO) may explain bloating in IBS is supported by greater total

JAMA2004

128. General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study.

General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study. OBJECTIVES: To compare general practitioners' perceptions of chronic fatigue syndrome and irritable bowel syndrome and to consider the implications of their perceptions for treatment. DESIGN: Qualitative analysis of transcripts of group discussions. PARTICIPANTS AND SETTING: A randomly selected sample of 46 general practitioners in England (...) with chronic fatigue syndrome. For both conditions many participants would not consider referral for mental health interventions, even though the doctors recognised social and psychological factors, because they were not familiar with the interventions or thought them unavailable or unnecessary. CONCLUSIONS: Barriers to the effective clinical management of patients with irritable bowel syndrome and chronic fatigue syndrome are partly due to doctors' beliefs, which result in negative stereotyping

BMJ2004 Full Text: Link to full Text with Trip Pro

129. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis

Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis Lackner J M, Morley S, Dowzer C, Mesmer C, Hamilton S CRD summary This generally well-conducted meta-analysis looked at the effect of a range of different psychological treatments for improving symptoms related (...) to irritable bowel syndrome. Though the authors concluded that psychological treatment appears beneficial, they added that the available evidence did not allow them to investigate the effects of any specific approach to psychological treatment. A more focused meta-analysis might have been more appropriate. Authors' objectives To assess the quality of existing literature on psychological treatments for irritable bowel syndrome (IBS) and to quantify the evidence for their efficacy. Searching The Cochrane

DARE.2004

130. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis

Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Mein S M, Ladabaum U Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Testing with tissue transglutaminase (TTG) antibodies alone, testing with a panel of antibodies (antigliadin IgG and antigliadin IgA), and up-front small bowel biopsy were compared with no testing for the detection of coeliac disease in patients with suspected irritable bowel syndrome

NHS Economic Evaluation Database.2004

131. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Spiegel B M R, DeRosa V P, Gralnek I M, Wang V, Dulai G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two strategies for the management of patients with who met the Rome II criteria for diarrhoea-predominant irritable bowel syndrome (IBS-D) were compared. The first was the direct initiation of empirical IBS treatment. The second was initial screening for coeliac sprue (CS). In the second

NHS Economic Evaluation Database.2004

132. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Cremonini F, Delgado-Aros S, Camilleri M CRD summary This review analysed six trials on the effects of alosetron in irritable bowel syndrome (IBS). The authors concluded that alosetron can improve (...) symptoms or decrease pain in female IBS patients without constipation. However, they also concluded that alosetron can have adverse effects, particularly constipation. The effects in men are unclear. These conclusions are appropriate given the evidence available. Authors' objectives To determine the effect of alosetron therapy on adequate relief of pain or global improvement of symptoms in patients with irritable bowel syndrome (IBS). Searching MEDLINE (from 1966 to 2002) and EMBASE (from 1988 to 2002

DARE.2003

133. A systematic review of alternative therapies in the irritable bowel syndrome

A systematic review of alternative therapies in the irritable bowel syndrome A systematic review of alternative therapies in the irritable bowel syndrome A systematic review of alternative therapies in the irritable bowel syndrome Spanier J A, Howden C W, Jones M P CRD summary This review concluded that there is no strong evidence for the effectiveness of alternative therapies in the treatment of irritable bowel syndrome. This was a poorly conducted review and it is unlikely that the findings (...) are reliable. Authors' objectives To review the available literature on alternative or complementary treatments for irritable bowel syndrome (IBS). Searching MEDLINE was searched from 1966 to 2001 for full papers in the English language. The bibliographies of included studies were also checked. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible for inclusion. Some of the included studies were uncontrolled studies. Specific interventions

DARE.2003

134. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatments for patients with severe irritable bowel syndrome (IBS) were examined. The treatments were psychotherapy (PSY) and antidepressant therapy with paroxetine (PAR; a selective serotonin reuptake inhibitor). PSY consisted of psychodynamic interpersonal therapy. The patients received one long

NHS Economic Evaluation Database.2003

135. Irritable bowel syndrome: a little understood organic bowel disease?

Irritable bowel syndrome: a little understood organic bowel disease? Irritable bowel syndrome affects 10% of adults with an unexplained female predominance. Although only a few people see their family doctor, the disease causes reduced quality of life and represents a multi-billion pound health-care problem. The disorder clusters in families, which is possibly because of intra-familial learning and a genetic predisposition. Visceral hypersensitivity is a key feature in most patients. Results (...) of imaging studies of regional cerebral blood flow during rectal distension suggest underlying disturbances of central processing of afferent signals, though this is not unique to the disorder, since it is seen in other chronic pain syndromes. Environmental factors that are strongly implicated in at least some patients include gastrointestinal infection and inflammation and chronic stress. Diagnosis is based on positive symptoms and absence of any alarm indicators. Treatment remains unsatisfactory

Lancet2002

136. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review Cash B D, Schoenfeld P, Chey W D Authors' objectives To quantify the prevalence of organic gastrointestinal (GI) disease, and to estimate the diagnostic accuracy of the most commonly used tests for organic GI disease amongst (...) patients who meet symptom-based criteria for irritable bowel syndrome (IBS). Searching MEDLINE and EMBASE were searched from 1980 to 2001; the search terms were reported. Bibliographies of retrieved articles and abstracts from the meetings of two American gastroenterology societies were also searched. Study selection Study designs of evaluations included in the review Study designs were not specified as part of the inclusion criteria. There was a mixture of case-control and cohort studies. Specific

DARE.2002

137. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care.

Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. BACKGROUND: Irritable bowel syndrome has a high prevalence. Consensus diagnostic criteria (ROME II) based on symptoms have been established to aid diagnosis. Although coeliac disease can be misdiagnosed as irritable bowel syndrome, no prospective study has been published in which patients with this disorder are investigated for coeliac (...) disease. We aimed to assess the association of coeliac disease with irritable bowel syndrome in patients fulfilling ROME II criteria. METHODS: We undertook a case-control study at a university hospital. 300 consecutive new patients who fulfilled Rome II criteria for irritable bowel syndrome, and 300 healthy controls (age and sex matched) were investigated for coeliac disease by analysis of serum IgA antigliadin, IgG antigliadin, and endomysial antibodies (EMA). Patients and controls with positive

Lancet2001

138. Tegaserod (Zelmac) (irritable bowel syndrome)

Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Stachnik J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stachnik J. Tegaserod (Zelmac) (irritable bowel syndrome) University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs

Health Technology Assessment (HTA) Database.2001

139. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome Poynard T, Regimbeau C, Benhamou Y Authors' objectives To assess the efficacy and tolerance of smooth muscle relaxants in the treatment of irritable bowel syndrome (IBS). Searching A search of MEDLINE and a manual search were combined (...) . The keywords used were 'colonic disease', 'functional', irritable bowel syndrome' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents, and by contacting pharmaceutical companies. In addition, recent meta-analyses in the Journal of Hepatogastroenterology were also used. Only published articles were considered for the review. Study selection Study designs of evaluations included in the review Only double-blind, placebo

DARE.2001

140. Treatment of irritable bowel syndrome: a review of randomised controlled trials

Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Akehurst R, Kaltenthaler E Authors' objectives To review and assess published randomised controlled trials (RCTs) examining the clinical effectiveness of interventions for irritable bowel syndrome (IBS) treatments. Searching The Cochrane Library, DARE (...) on motility were excluded. Participants included in the review Patients with IBS. No further details of the participants were reported. Outcomes assessed in the review A range of outcome measures were reported including the following: nausea, vomiting, abdominal pain, bowel habit, distension, overall symptom scores, depression, well-being and pain relief. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many

DARE.2001